Drugs / Therapeutic EGF Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01444118 | Nov 2011 → Dec 2014 | non-small cell lung carcinoma | Bioven Europe | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Therapeutic EGF Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01444118 ↗ |
| Known as | rEGF-P64K/Montanide ISA 51 vaccine | “Therapeutic EGF Vaccine (Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine)” NCT01444118 ↗ |
| Action | Inhibit | “The antibodies induced by vaccination will react with circulating EGF leading to removal of EGF from the circulation.” NCT01444118 ↗ |
| Modality | Vaccine | “The vaccine contains humanized recombinant antigen (Epithelial Growth Factor) and an adjuvant.” NCT01444118 ↗ |